Of the 1,691 surveyed, 969 (57%) obtained travel medicine advice from various sources and 543 (32%) visited a health care provider to prepare for their trip. Travelers returning to their birth country were less likely to visit a health care provider to prepare for their trip (110/527, PI3K Inhibitor Library 19%) compared to other travelers (433/1,113, 34%) (PR 0.6, 95% CI: 0.5–0.7). On the basis of their reported itineraries, 415 (25%) of the surveyed travelers were classified as having higher risk for JE virus exposure and 1,276 (75%) were classified as lower JE risk. Travelers with higher JE risk itineraries (mean age 41 years) were younger than travelers

with lower JE risk itineraries (mean age 46 years; difference 5.1 years, 95% CI: 1.1–9.1). Higher and lower JE risk travelers were similar with regard to education level, household income, and planned destination countries. However, to prepare for their current trip, higher risk travelers were more likely to have visited a health care provider (185/415, 45%) than lower risk travelers (360/1,276, 28%) (PR 1.6, 95% CI: 1.2–2.1). Of the 415 travelers with higher JE risk itineraries, Cobimetinib nmr 330 (84%, 95% CI: 79–88%) planned to spend ≥1 month in a JE-endemic country, including 115 (37%, 95% CI 26–47%) planning to spend ≥6 months in Asia. The remaining 85 (16%, 95% CI: 12–21%) higher JE risk travelers planned

to spend <1 month in Asia but at least half of their time in rural areas; of these, 55 (62%, 95% CI: 49–77%) planned to spend more than half of their time doing outdoor activities in rural areas. Among the higher JE risk travelers, those returning to their birth country were again less likely to visit a health care provider to prepare for their trip (21% vs 56%; PR 0.4, 95% CI: 0.3–0.5). find more Forty-seven (11%, 95% CI: 7–15%) of the higher JE

risk travelers reported that they received ≥1 doses of JE vaccine for this trip or a previous trip, while 368 (89%, 95% CI: 85–93%) indicated that they had never received JE vaccine. Higher risk travelers who received JE vaccine (mean age 34 years) were significantly younger than those who did not receive JE vaccine (mean age 41 years; difference 6.0 years, 95% CI: 0.1–12.9 years). Of the 368 travelers who were classified as higher JE risk but who had not received JE vaccine, 219 (60%) were unaware of or had not been advised to receive vaccine, and 104 (28%) did not think they needed JE vaccine for their trip. Overall, 164 (45%) of the 368 unvaccinated higher risk travelers visited a health care provider to prepare for the trip, but 113 (69%) still indicated that they had never heard of JE vaccine or their health care provider did not advise the JE vaccine (Table 3). Vaccine costs (7/164, 4%), inadequate time prior to travel (3/164, 2%), and concerns about possible adverse events (1/164, <1%) were uncommon reasons reported for not receiving the vaccine.